Introduction/Background The incidence of brain metastases (BMs) from ovarian cancer ranges at about 1%. - 3%. Although brain metastasis development is very rare in ovarian cancer, it should be considered in the patient group with poor prognostic features, especially at the time of high-grade diagnosis.

Methodology We aimed to analyze patients with brain metastasis from ovarian cancer (OC), fallopian tube carcinoma (FTC), primary peritoneal carcinoma (PPC) in a single center experience and calculate overall survival (OS), disease-free (DFS) interval between diagnosis of OC and BMs.

Methods All women with OC, FTC and PPC with BMs, who were treated in Oncogynecological Department of N.N. Alexandrov National Cancer Centre of Belarus between January 1980 and December 2022 were retrospectively identified. The main criteria were serous carcinoma, endometrioid carcinoma and clear cell carcinoma and brain metastasis. All data and follow-up were taken from medical records and analyzed then. DFS and OS were studied with the use of Kaplan-Meier curves. All computations were performed using SPSS Statistics (version 23.0).

Results 106 patients with BMs met the inclusion criteria. A total of 105 patients were analyzed: all patients with OC. The mean was 61.42 ± 9.94 (95% CI [59.52; 63.32]) years. A multimodal approach (surgery combined with radiotherapy and chemotherapy) used in 21% of patients with BMs. The overall five-year survival of patients with OC with BMs was 35.7%, while one-year DFS was 67.9%. Median time to development of brain metastases was 31 ± 2.4 (95% CI [17.35; 141.4]) months.

Conclusion The overall five-year survival of patients with OC with BMs was 35.7%. Median time of brain metastases development was 31 months.

Disclosures The authors have nothing to disclose.